FY2025 EPS Estimates for ACAD Decreased by Zacks Research
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Zacks Research cut their FY2025 EPS estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $0.51 per share for the year, down from their previous estimate of $0.68. The consensus […]
More Stories
Trump’s 3D Chess: How President Trump Is Checkmating China and Russia by Toppling Their Oil Proxies in Venezuela, Cuba, and Iran
By Stephen Zogopoulos, USNN World News In the rarefied world of grand strategy, true masters don’t play on a flat...
Iran Vows Lasting Grip on Strait of Hormuz After War
By Tom Ozimek Iran has signaled that it intends to exert lasting control over the Strait of Hormuz—the world’s most...
Trump Signs Memo to Pay All DHS Employees During Shutdown
By Troy Myers President Donald Trump on Friday signed a memorandum directing the Department of Homeland Security (DHS) to pay...
Best Photo Editing Apps in 2026: Features, Pricing, and Limitations
Finding the best photo editing app in 2026 has become difficult. With several Android and iOS editing tools available in...
In the Mud Season 3: Release Date, Cast, Trailer, and Spoiler
If you have already watched the first two seasons of In the Mud, then you must also be curious about...
US Deployments Fuel Speculation of Ground Combat Against Iran
By Ryan Morgan The U.S. military has deployed several thousand additional infantry troops to the Middle East in recent weeks,...